These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 11294508

  • 1. Evaluation of synthetic schemes to prepare immunogenic conjugates of Vibrio cholerae O139 capsular polysaccharide with chicken serum albumin.
    Kossaczka Z, Szu SC.
    Glycoconj J; 2000 Jun; 17(6):425-33. PubMed ID: 11294508
    [Abstract] [Full Text] [Related]

  • 2. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.
    Kossaczka Z, Shiloach J, Johnson V, Taylor DN, Finkelstein RA, Robbins JB, Szu SC.
    Infect Immun; 2000 Sep; 68(9):5037-43. PubMed ID: 10948122
    [Abstract] [Full Text] [Related]

  • 3. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
    Kamruzzaman M, Kelly M, Charles RC, Harris JB, Calderwood SB, Akter A, Biswas R, Kaisar MH, Bhuiyan TR, Ivers LC, Ternier R, Jerome JG, Pfister HB, Lu X, Soliman SE, Ruttens B, Saksena R, Mečárová J, Čížová A, Qadri F, Bystrický S, Kováč P, Xu P, Ryan ET.
    mSphere; 2021 Aug 25; 6(4):e0011421. PubMed ID: 34232076
    [Abstract] [Full Text] [Related]

  • 4. Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.
    Jin Z, Chu C, Robbins JB, Schneerson R.
    Infect Immun; 2003 Sep 25; 71(9):5115-20. PubMed ID: 12933854
    [Abstract] [Full Text] [Related]

  • 5. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J.
    Vaccine; 2000 Nov 22; 19(7-8):850-61. PubMed ID: 11115709
    [Abstract] [Full Text] [Related]

  • 6. Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodies.
    Attridge SR, Holmgren J.
    Microb Pathog; 2009 Dec 22; 47(6):314-20. PubMed ID: 19818394
    [Abstract] [Full Text] [Related]

  • 7. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid.
    Boutonnier A, Villeneuve S, Nato F, Dassy B, Fournier JM.
    Infect Immun; 2001 May 22; 69(5):3488-93. PubMed ID: 11292781
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of different subcellular fractions of Vibrio cholerae O139 in protection to challenge in experimental cholera.
    Bondre VP, Sinha VB, Srivastava BS.
    FEMS Immunol Med Microbiol; 1997 Dec 22; 19(4):323-9. PubMed ID: 9537758
    [Abstract] [Full Text] [Related]

  • 9. Immunomodulation of T-cell responses with Vibrio cholerae O135 capsular polysaccharide and its protein conjugate, novel cholera vaccine study models.
    Paulovičová E, Korcová J, Machová E, Bystrický S.
    FEMS Immunol Med Microbiol; 2012 Aug 22; 65(3):422-30. PubMed ID: 22443716
    [Abstract] [Full Text] [Related]

  • 10. Differential immunogenicity of Vibrio cholerae O139 variants expressing different combinations of naturally occurring and atypical forms of the serogroup polysaccharide.
    Attridge SR, Wallerström G, Li BL, Morona R, Holmgren J.
    Vaccine; 2009 Feb 11; 27(7):1055-61. PubMed ID: 19100303
    [Abstract] [Full Text] [Related]

  • 11. Preliminary structure determination of the capsular polysaccharide of Vibrio cholerae O139 Bengal Al1837.
    Preston LM, Xu Q, Johnson JA, Joseph A, Maneval DR, Husain K, Reddy GP, Bush CA, Morris JG.
    J Bacteriol; 1995 Feb 11; 177(3):835-8. PubMed ID: 7836323
    [Abstract] [Full Text] [Related]

  • 12. Peptides mimicking Vibrio cholerae O139 capsular polysaccharide elicit protective antibody response.
    Falklind-Jerkérus S, Felici F, Cavalieri C, Lo Passo C, Garufi G, Pernice I, Islam MM, Qadri F, Weintraub A.
    Microbes Infect; 2005 Dec 11; 7(15):1453-60. PubMed ID: 16046165
    [Abstract] [Full Text] [Related]

  • 13. Construction and characterization of a potential live oral carrier-based vaccine against Vibrio cholerae O139.
    Favre D, Cryz SJ, Viret JF.
    Infect Immun; 1996 Sep 11; 64(9):3565-70. PubMed ID: 8751900
    [Abstract] [Full Text] [Related]

  • 14. Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh.
    Qadri F, Svennerholm AM, Shamsuzzaman S, Bhuiyan TR, Harris JB, Ghosh AN, Nair GB, Weintraub A, Faruque SM, Ryan ET, Sack DA, Calderwood SB.
    Infect Immun; 2005 Oct 11; 73(10):6577-83. PubMed ID: 16177333
    [Abstract] [Full Text] [Related]

  • 15. Preparation and immunogenicity of conjugate based on hydrazine-treated lipopolysaccharide antigen of Vibrio cholerae O139.
    Fleischhackerová A, Farkaš P, Cížová A, Bystrický S.
    Biosci Biotechnol Biochem; 2014 Oct 11; 78(11):1817-24. PubMed ID: 25070088
    [Abstract] [Full Text] [Related]

  • 16. Antibodies to the truncated (short) form of 'O' polysaccharides (TFOP) of Vibrio cholerae O139 lipopolysaccharides protect mice against experimental cholera induced by encapsulated O139 strains and such protection is mediated by inhibition of intestinal colonization of vibrios.
    Nandy RK, Mukhopadhyay S, Ghosh AN, Ghose AC.
    Vaccine; 1999 Jul 16; 17(22):2844-52. PubMed ID: 10438055
    [Abstract] [Full Text] [Related]

  • 17. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.
    Konadu E, Shiloach J, Bryla DA, Robbins JB, Szu SC.
    Infect Immun; 1996 Jul 16; 64(7):2709-15. PubMed ID: 8698499
    [Abstract] [Full Text] [Related]

  • 18. A review of the current status of enteric vaccines.
    Levine MM, Noriega F.
    P N G Med J; 1995 Dec 16; 38(4):325-31. PubMed ID: 9522876
    [Abstract] [Full Text] [Related]

  • 19. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers.
    Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SC.
    Infect Immun; 1998 Jul 16; 66(7):3095-9. PubMed ID: 9632571
    [Abstract] [Full Text] [Related]

  • 20. Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier.
    Chernyak A, Kondo S, Wade TK, Meeks MD, Alzari PM, Fournier JM, Taylor RK, Kovác P, Wade WF.
    J Infect Dis; 2002 Apr 01; 185(7):950-62. PubMed ID: 11920320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.